
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastroenterology 2025;169:1547–1557</li>
<li style="margin-left: 0px;">Topic: Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis</li>
<li style="margin-left: 0px;">Author(s): Eric S. Orman, Brett E. Fortune, Binu V. John, Sumeet K. Asrani</li>
</ul>
<details><summary><strong>1. Pathophysiology of Volume Overload in Cirrhosis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Mechanism</strong>: Portal hypertension → increased intrahepatic vascular resistance + portal blood flow → mesenteric and systemic vasodilation → neurohormonal activation (RAAS) → renal sodium/water reabsorption → intravascular/interstitial volume expansion</li>
<li style="margin-left: 0px;"><strong>Ascites formation</strong>: Excess fluid leaks into peritoneal cavity when hepatic lymphatic system capacity exceeded; occurs with hypoalbuminemia (↓ oncotic pressure), ↑ hydrostatic pressure (portal hypertension), and increased capillary permeability</li>
<li style="margin-left: 0px;"><strong>Hepatic hydrothorax (HH)</strong>: Diaphragmatic defects allow ascitic fluid translocation into pleural space</li>
<li style="margin-left: 0px;"><strong>Peripheral edema/anasarca</strong>: Interstitial fluid accumulation in peripheral tissues</li>
<li style="margin-left: 0px;"><strong>Hyponatremia</strong>: Progressive circulatory dysfunction → effective intravascular hypovolemia → ↑ renal water retention → hypervolemic hyponatremia</li>
<li style="margin-left: 0px;"><strong>Clinical impact</strong>: ↓ quality of life, repeated hospitalizations, predisposes to infections/hepatorenal syndrome, ↑ mortality</li>
</ul>
</div></details>
<details><summary><strong>2. Best Practice Advice 1: Initial Management of Ascites, HH, and Volume Overload</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Patients with cirrhosis + ascites/HH/volume overload → managed with dietary sodium restriction + diuretics at lowest effective dose</li>
<li style="margin-left: 0px;"><strong>Dose escalation</strong> guided by: symptoms, weight, urine output, electrolyte/renal monitoring</li>
<li style="margin-left: 0px;"><strong>Dietary sodium</strong>: Target &lt;2000 mg/d; referral to dietitian for label reading, cooking techniques, patient/caregiver education</li>
<li style="margin-left: 0px;"><strong>Dietary requirements</strong>: ≥35 kcal/kg/d (non-obese), protein 1.2–1.5 g/kg/d, micronutrient repletion; avoid overly restrictive diets causing caloric/protein deficiency</li>
<li style="margin-left: 0px;"><strong>Fluid restriction</strong>: Not needed unless significant hyponatremia present</li>
<li style="margin-left: 0px;"><strong>First-line diuretics</strong>: Mineralocorticoid receptor antagonists + loop diuretics combined (furosemide:spironolactone 40:100 ratio)</li>
<li style="margin-left: 0px;"><strong>Spironolactone</strong>: Start 100 mg/d (range 50–400 mg), once-daily morning dose; alternatives: amiloride, eplerenone for intolerance</li>
<li style="margin-left: 0px;"><strong>Furosemide</strong>: Start 40 mg/d (range 20–160 mg), titrate by ascites severity, BP, electrolytes, renal function</li>
<li style="margin-left: 0px;"><strong>Monitoring</strong>: Patient self-weighing daily; target weight loss 0.5 kg/d (without edema) or 1 kg/d (with edema)</li>
<li style="margin-left: 0px;"><strong>Triggers of decompensation</strong>: Identify and address (alcohol, medications, hemodynamic changes, infection); may need to hold BP medications (especially renin-angiotensin system inhibitors)</li>
</ul>
</div></details>
<details><summary><strong>3. Best Practice Advice 2: Diagnostic Paracentesis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Indications</strong>: New-onset ascites OR hospitalization for ascites-related symptoms/encephalopathy → receive diagnostic paracentesis ASAP</li>
<li style="margin-left: 0px;"><strong>Testing required</strong>: Serum ascites albumin gradient (SAAG), cell count, Gram stain, culture</li>
<li style="margin-left: 0px;"><strong>SAAG interpretation</strong>: ≥1.1 g/dL suggests portal hypertension; &lt;1.1 g/dL warrants evaluation for other causes (heart failure, malignancy, tuberculosis)</li>
<li style="margin-left: 0px;"><strong>SBP diagnosis</strong>: Neutrophil count &gt;250/mm³ with/without culture positivity, no secondary peritonitis evidence</li>
<li style="margin-left: 0px;"><strong>Culture method</strong>: Bedside inoculation into blood culture bottles</li>
<li style="margin-left: 0px;"><strong>Timing</strong>: Paracentesis within 12–24 hours of admission → associated with lower hospital mortality</li>
<li style="margin-left: 0px;"><strong>Additional testing</strong> if low SAAG or non-portal hypertension features: cytology, amylase, mycobacterial studies</li>
</ul>
</div></details>
<details><summary><strong>4. Best Practice Advice 3: Hepatic Hydrothorax Management</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Definition</strong>: Pleural effusion in portal hypertension setting without other causes (heart failure, lung disease, malignancy)</li>
<li style="margin-left: 0px;"><strong>Prognosis</strong>: Poor prognostic sign; &gt;4-fold ↑ mortality vs. refractory ascites alone</li>
<li style="margin-left: 0px;"><strong>Diagnostic thoracentesis</strong>: Excludes other causes; evaluate for spontaneous bacterial empyema (SBE)</li>
<li style="margin-left: 0px;"><strong>SBE diagnosis</strong>: Pleural fluid neutrophils &gt;250/mm³ with/without culture positivity, no alternative infectious source</li>
<li style="margin-left: 0px;"><strong>Therapeutic thoracentesis</strong>: Indicated for dyspnea and/or hypoxemia → symptom relief + lung expansion</li>
<li style="margin-left: 0px;"><strong>First-line therapy</strong>: Sodium restriction + diuretics (same as ascites)</li>
<li style="margin-left: 0px;"><strong>Symptom threshold</strong>: HH causes symptoms at much lower fluid volumes vs. ascites</li>
</ul>
</div></details>
<details><summary><strong>5. Best Practice Advice 4: Liver Transplantation Evaluation</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>All patients with ascites and/or HH</strong> should be considered for liver transplantation evaluation, regardless of MELD score</li>
<li style="margin-left: 0px;"><strong>Ascites significance</strong>: Most common initial decompensation event; marks critical step in disease natural history</li>
<li style="margin-left: 0px;"><strong>Mortality impact</strong>: Once ascites develops, annual mortality rises from &lt;5% to ~20%; 90-day mortality up to 50% for SBP/hepatorenal syndrome</li>
<li style="margin-left: 0px;"><strong>Associated complications</strong>: Links to malnutrition, sarcopenia, frailty → ↑ mortality and potential transplantation preclusion</li>
<li style="margin-left: 0px;"><strong>MELD considerations</strong>: Revised MELD includes sodium, sex, albumin to better reflect waitlist mortality and reduce disparities; ascites remains independent predictor of mortality beyond MELD</li>
<li style="margin-left: 0px;"><strong>Transplant access</strong> for low-MELD ascites patients: living donors, extended criteria donors</li>
<li style="margin-left: 0px;"><strong>HH-specific mortality</strong>: Independently associated with significantly higher mortality regardless of MELD; 1-year mortality 20%–50%</li>
<li style="margin-left: 0px;"><strong>HH MELD exception</strong>: No standard OPTN exception; nonstandard exceptions may be granted for: ≥1 thoracentesis &gt;1 L weekly × 4 weeks, transudative fluid, no heart failure, negative cultures/cytology, TIPS contraindications</li>
</ul>
</div></details>
<details><summary><strong>5. Best Practice Advice 5: Management of Refractory Ascites and Hepatic Hydrothorax</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Refractory ascites definition</strong>: Ascites that cannot be mobilized OR early recurrence cannot be satisfactorily prevented by medical therapy</li>
<li style="margin-left: 0px;"><strong>Subcategories</strong>: Diuretic-resistant (nonresponse to sodium restriction + diuretics) vs. diuretic-intractable (complications preventing effective dose escalation)</li>
<li style="margin-left: 0px;"><strong>Refractory HH definition</strong>: Unresponsive to salt restriction and diuretic therapy, requires therapeutic thoracentesis</li>
<li style="margin-left: 0px;"><strong>Therapeutic paracentesis</strong>: Safe, effective method; faster symptom relief vs. intensive diuretic therapy with fewer complications (HE, electrolyte abnormalities, AKI)</li>
<li style="margin-left: 0px;"><strong>Postparacentesis circulatory dysfunction</strong>: Marked by ↓ systemic vascular resistance + RAAS/sympathetic system activation → ↑ risks of kidney injury, electrolyte imbalances, HE, death</li>
<li style="margin-left: 0px;"><strong>Bleeding risk</strong>: Rare even with coagulopathy/thrombocytopenia; prophylactic transfusions not advised</li>
<li style="margin-left: 0px;"><strong>Refractory HH challenges</strong>: Lower fluid thresholds for symptoms vs. ascites; presents as dyspnea vs. distention</li>
<li style="margin-left: 0px;"><strong>Thoracentesis risks</strong>: Higher than for other effusions (bleeding, infection, pneumothorax, re-expansion edema); chest wall portosystemic collaterals can cause catastrophic bleeding</li>
<li style="margin-left: 0px;"><strong>Chest tube placement</strong>: High morbidity/mortality → should be avoided in HH</li>
<li style="margin-left: 0px;"><strong>Indwelling tunneled pleural catheters</strong>: Promising option with relatively low complication rates; palliative for non-transplant candidates or bridge to transplantation with short wait times</li>
</ul>
</div></details>
<details><summary><strong>6. Best Practice Advice 6: Albumin Administration Post-Paracentesis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Standard protocol</strong>: When ascites removed &gt;5 L → administer 20%–25% IV albumin 6–8 g per every total liter removed</li>
<li style="margin-left: 0px;"><strong>Rationale</strong>: Prevents postparacentesis circulatory dysfunction → reduces electrolyte derangements and mortality</li>
<li style="margin-left: 0px;"><strong>5 L cutoff</strong>: Somewhat arbitrary; recent data suggest smaller-volume paracentesis may also benefit from albumin</li>
<li style="margin-left: 0px;"><strong>Dose-defining studies</strong>: Needed; different albumin doses have not shown outcome differences</li>
<li style="margin-left: 0px;"><strong>Liberal albumin strategy</strong> considerations: For patients with hypotension, renal insufficiency, or electrolyte abnormalities → more severe postparacentesis circulatory dysfunction consequences</li>
<li style="margin-left: 0px;"><strong>Case-by-case approach</strong>: Lower-volume thresholds and higher doses may be considered; avoid iatrogenic volume overload</li>
</ul>
</div></details>
<details><summary><strong>7. Best Practice Advice 7: Transjugular Intrahepatic Portosystemic Shunt (TIPS) Referral</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Indication</strong>: Well-selected patients with refractory ascites, HH, volume overload, or hyponatremia</li>
<li style="margin-left: 0px;"><strong>Efficacy</strong>: Highly effective for portal hypertension; more effective than paracentesis for ascites control; associated with lower mortality</li>
<li style="margin-left: 0px;"><strong>Patient-reported outcomes</strong>: Less clear; symptom relief may be offset by HE and TIPS dysfunction risk</li>
<li style="margin-left: 0px;"><strong>Contemporary stents</strong>: Polytetrafluoroethylene-covered stents may reduce risks, although data limited</li>
<li style="margin-left: 0px;"><strong>Absolute contraindications</strong>: Congestive heart failure, severe pulmonary hypertension, uncontrolled HE, sepsis</li>
<li style="margin-left: 0px;"><strong>Relative contraindications</strong>: Ejection fraction &lt;50%, severe diastolic/valvular dysfunction, right ventricular systolic pressure &gt;45 mm Hg</li>
<li style="margin-left: 0px;"><strong>HE risk</strong>: Occurs in up to 50% post-TIPS; risk factors include prior HE, impaired liver function, older age, renal dysfunction, hyponatremia, large gradient reduction, sarcopenia</li>
<li style="margin-left: 0px;"><strong>Caution populations</strong>: Patients &gt;70 years or MELD &gt;18; indication increasingly expanded</li>
<li style="margin-left: 0px;"><strong>Cardiac decompensation risk</strong>: Up to 20% within 1 year of TIPS</li>
<li style="margin-left: 0px;"><strong>Preprocedural evaluation</strong>: Echocardiography for cardiac systolic/diastolic function and RVSP</li>
<li style="margin-left: 0px;"><strong>Optimal timing</strong>: Undefined; most studies focus on refractory ascites/HH</li>
<li style="margin-left: 0px;"><strong>Early TIPS strategy evidence</strong>: Patients with &lt;6 paracenteses in 3 months showed better ascites control, fewer hospitalizations, improved survival without more HE</li>
<li style="margin-left: 0px;"><strong>Cost-effectiveness</strong>: Early TIPS may be cost-effective but needs validation</li>
<li style="margin-left: 0px;"><strong>Expert panel suggestion</strong>: TIPS after 3 large-volume paracenteses in 12 months, especially with other indications (e.g., prior variceal bleeding)</li>
<li style="margin-left: 0px;"><strong>Non-TIPS candidates</strong>: Limited evidence supports indwelling peritoneal catheters; complication rates may be high</li>
<li style="margin-left: 0px;"><strong>Alfapump system</strong>: Transfers ascites into bladder; improved quality of life in RCTs; infection risk; recently approved in US, widespread experience lacking</li>
<li style="margin-left: 0px;"><strong>Peritoneovenous shunt</strong>: Consideration for select non-TIPS candidates; limited by shunt patency concerns, DIC, heart failure</li>
</ul>
</div></details>
<details><summary><strong>8. Best Practice Advice 8: Diagnostic Workup for Hyponatremia in Cirrhosis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Hyponatremia definition</strong>: Serum sodium &lt;130 mEq/L in cirrhosis</li>
<li style="margin-left: 0px;"><strong>Pathophysiology</strong>: Hypervolemic hyponatremia from serum overdilution due to fluid retention from vasopressin secretion → ↑ water reabsorption → enhanced sodium reabsorption</li>
<li style="margin-left: 0px;"><strong>Significance</strong>: Associated with significant morbidity and mortality; serum sodium incorporated into transplant allocation system within MELD</li>
<li style="margin-left: 0px;"><strong>Components of workup</strong>:</li>
<li style="margin-left: 20px;">Dietary and medication history (diuretics, bowel regimen)</li>
<li style="margin-left: 20px;">Review of electrolyte and kidney function</li>
<li style="margin-left: 20px;">Gastrointestinal bleeding assessment</li>
<li style="margin-left: 20px;">Infectious workup including diagnostic paracentesis</li>
<li style="margin-left: 20px;">Evaluation of secondary causes (thyroid or adrenal dysfunction)</li>
<li style="margin-left: 0px;"><strong>Daily documentation</strong>: Sodium and fluid intake, alcohol use, medications</li>
<li style="margin-left: 0px;"><strong>Additional assessments</strong>: Renal, thyroid, adrenal, cardiac function</li>
<li style="margin-left: 0px;"><strong>Infection evaluation</strong>: Essential; hyponatremia may signal acute inflammation; include cultures and diagnostic paracentesis</li>
<li style="margin-left: 0px;"><strong>Pseudohyponatremia</strong>: Laboratory artifact in hypertriglyceridemia or paraproteinemia; consider if serum osmolality not low (&gt;280 mOsm/L)</li>
<li style="margin-left: 0px;"><strong>Nonhepatic causes</strong>: If identified, targeted management follows standard protocols</li>
</ul>
</div></details>
<details><summary><strong>9. Best Practice Advice 9: Outpatient Management of Asymptomatic Hypervolemic Hyponatremia</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Management approach</strong>: Sodium + water restriction based on hyponatremia severity</li>
<li style="margin-left: 0px;"><strong>Mild hyponatremia</strong> (serum sodium &gt;120 mEq/L) + asymptomatic: Limit fluid intake to 1–1.5 L/d</li>
<li style="margin-left: 0px;"><strong>Diuretic adjustment</strong>: Often need to reduce or discontinue diuretics</li>
<li style="margin-left: 0px;"><strong>Sodium stabilization</strong>: Once sodium stabilizes &gt;125 mEq/L, providers can resume or maintain diuretics</li>
<li style="margin-left: 0px;"><strong>Lactulose/ laxative education</strong>: Important to avoid excessive stooling → volume depletion → worsening hyponatremia</li>
<li style="margin-left: 0px;"><strong>Monitoring</strong>: Serial electrolyte and renal function monitoring is critical</li>
<li style="margin-left: 0px;"><strong>Ambulatory albumin infusions</strong>: May help hyponatremia; data sparse; access limited by insurance and infusion site availability</li>
</ul>
</div></details>
<details><summary><strong>10. Best Practice Advice 10: Inpatient Management of Severe/Symptomatic Hypervolemic Hyponatremia</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Hospitalization criteria</strong>: Symptoms related to hyponatremia OR serum sodium &lt;120 mEq/L</li>
<li style="margin-left: 0px;"><strong>Symptoms</strong>: Cognitive changes, dizziness, seizures, cardiopulmonary alterations, nausea, vomiting</li>
<li style="margin-left: 0px;"><strong>Precipitant evaluation</strong>: Include infections; assess for precipitating factors</li>
<li style="margin-left: 0px;"><strong>Immediate actions</strong>:</li>
<li style="margin-left: 20px;">Discontinue or adjust diuretics and laxatives</li>
<li style="margin-left: 20px;">Assess renal and cardiac function</li>
<li style="margin-left: 20px;">Correct hypokalemia especially with encephalopathy</li>
<li style="margin-left: 20px;">Fluid intake restricted to less than urine output</li>
<li style="margin-left: 0px;"><strong>Hypotension management</strong> (SBP &lt;90 mm Hg): Hold nonselective beta-blockers for portal hypertension; endoscopic management of high-risk varices if unable to resume beta-blockers</li>
<li style="margin-left: 0px;"><strong>Severe symptomatic cases</strong>: Immediate interventions—albumin infusion or vasoconstrictors (e.g., midodrine) → improve renal perfusion</li>
<li style="margin-left: 0px;"><strong>Life-threatening hyponatremia</strong> or correction needed before transplant: Cautious 3% hypertonic saline use; avoid rapid correction to prevent osmotic demyelination syndrome</li>
<li style="margin-left: 0px;"><strong>Vaptans (vasopressin antagonists)</strong>: Can improve hyponatremia in cirrhosis; use declined due to adverse events (hepatic injury, mortality); now reserved mainly for short-term use in severe hyponatremia awaiting liver transplantation</li>
<li style="margin-left: 0px;"><strong>Severe kidney injury</strong>: Hemodialysis may help correct hyponatremia</li>
</ul>
</div></details>
<details><summary><strong>11. Best Practice Advice 11: Recurrent or Refractory Hyponatremia Management</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Definition</strong>: Recurrent = redevelopment after prior episode; Refractory = persistence despite maximal therapy</li>
<li style="margin-left: 0px;"><strong>Epidemiology</strong>: Hyponatremia recurs in &gt;50% of cases; associated with poor survival</li>
<li style="margin-left: 0px;"><strong>Mortality significance</strong>: Ongoing hyponatremia carries significant short-term mortality; severity increases transplantation need</li>
<li style="margin-left: 0px;"><strong>Multidisciplinary approach required</strong>: Include transplant hepatology, nephrology, potentially anesthesiology</li>
<li style="margin-left: 0px;"><strong>Evaluation</strong>: Rule out other causes (e.g., adrenal insufficiency)</li>
<li style="margin-left: 0px;"><strong>Therapeutic options</strong>:</li>
<li style="margin-left: 20px;">Vasoconstrictor therapy (e.g., terlipressin or norepinephrine): May improve sodium levels before transplantation</li>
<li style="margin-left: 20px;">Hypertonic saline: For symptomatic or severe hyponatremia</li>
<li style="margin-left: 20px;">Vaptans: Team-based decision for short-term use</li>
<li style="margin-left: 20px;">Renal replacement therapy: If transplantation not an option, palliative care + hepatology for goals of care and symptom management</li>
</ul>
</div></details>
<details><summary><strong>12. Best Practice Advice 12: Inpatient Management of Volume Overload</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Clinical presentation</strong>: Anasarca with/without ascites or HH—common decompensation presentation in inpatient setting</li>
<li style="margin-left: 0px;"><strong>Inpatient management indication</strong>: Patients progressing despite outpatient diuretic escalation OR persistent anasarca/volume overload signs</li>
<li style="margin-left: 0px;"><strong>Evidence base</strong>: Focused study limited; guidance extrapolated from cardiology/nephrology literature</li>
<li style="margin-left: 0px;"><strong>First steps</strong>:</li>
<li style="margin-left: 20px;">Reverse aggravating factors (alcohol, NSAIDs)</li>
<li style="margin-left: 20px;">Dietary sodium restriction</li>
<li style="margin-left: 20px;">Medication review including anti-hypertensives (especially renin-angiotensin system inhibitors)</li>
<li style="margin-left: 20px;">Diuresis</li>
<li style="margin-left: 0px;"><strong>Goal</strong>: Promote urinary sodium excretion exceeding dietary sodium intake</li>
<li style="margin-left: 0px;"><strong>Initial regimens</strong>: IV loop diuretics (furosemide or bumetanide) in bolus (2–3 times daily) or continuous fashion</li>
<li style="margin-left: 0px;"><strong>Response monitoring</strong>: Daily symptom assessment, urine output, kidney function, weights</li>
<li style="margin-left: 0px;"><strong>Escalation</strong>: If inadequate diuresis, escalate doses in bolus or continuous fashion every 2–3 days with monitoring</li>
<li style="margin-left: 0px;"><strong>Bolus vs. continuous superiority</strong>: Unclear in cirrhosis</li>
<li style="margin-left: 0px;"><strong>First-line agent comparison</strong>: Furosemide and bumetanide likely similar efficacy; torsemide may also play role (only oral in US)</li>
<li style="margin-left: 0px;"><strong>Potency</strong>: IV furosemide ~2× potent as oral; bumetanide may have 1:1 oral-to-IV equivalence</li>
<li style="margin-left: 0px;"><strong>Concurrent IV albumin role</strong>: Unclear; targeting serum albumin level in patients not admitted for volume overload does not reduce infection, kidney dysfunction, or death</li>
</ul>
</div></details>
<details><summary><strong>13. Best Practice Advice 13: Advanced Strategies in Refractory Anasarca</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Coordination</strong>: Partner with nephrology for inadequate diuretic response</li>
<li style="margin-left: 0px;"><strong>Thiazide diuretics</strong> (e.g., metolazone): Consider in refractory edema unresponsive to loop diuretics</li>
<li style="margin-left: 0px;"><strong>Adverse events limiting diuresis</strong>: Contraction alkalosis, electrolyte dysfunction</li>
<li style="margin-left: 0px;"><strong>Serum creatinine elevation</strong>: Common but may not reflect worsening kidney function</li>
<li style="margin-left: 0px;"><strong>Diuretic-resistant anasarca definition</strong>: No improvement despite maximal diuretics + persistently low urine sodium</li>
<li style="margin-left: 0px;"><strong>Advanced strategies</strong>:</li>
<li style="margin-left: 20px;">Pressors to augment diuresis in ICU setting</li>
<li style="margin-left: 20px;">Ultrafiltration: Consider in select cases, especially liver transplantation candidates</li>
<li style="margin-left: 0px;"><strong>Discharge planning</strong>: Transitional care with proper medication management, patient/caregiver education, timely follow-up to improve outcomes</li>
</ul>
</div></details>
<details><summary><strong>14. Conclusions and Future Directions</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Curative option</strong>: Liver transplantation remains the only curative option for cirrhosis with ascites, fluid overload, hyponatremia</li>
<li style="margin-left: 0px;"><strong>Gap</strong>: Significant gap between donor organ supply and transplant demand → need for bridging strategies or quality of life improvement</li>
<li style="margin-left: 0px;"><strong>Research needs</strong>: Clear needs to improve management of ascites, fluid overload, hyponatremia; ongoing studies warranted</li>
<li style="margin-left: 0px;"><strong>Special population</strong>: Investigational therapeutic trials especially needed for advanced steatotic liver disease patients with significant comorbidities confounding older treatment paradigms</li>
<li style="margin-left: 0px;"><strong>Disease definition refinement</strong>: Needed to enhance provider understanding, enable earlier recognition and appropriate management implementation</li>
<li style="margin-left: 0px;"><strong>Care setting considerations</strong>: Many patients with complex fluid retention, ascites, hyponatremia managed at tertiary/transplantation centers; gastroenterologists and hospitalists must know when/how to provide optimal care and timely hepatology referral</li>
<li style="margin-left: 0px;"><strong>Outcome impact</strong>: Without successful linkage, patients may fail to connect with liver centers → higher mortality, readmissions, poor outcomes</li>
<li style="margin-left: 0px;"><strong>Future focus</strong>: Complement advances in treating underlying liver disease (e.g., metabolic dysfunction–associated steatotic liver disease) with improved strategies for fluid overload to enhance survival, quality of life, and hope for patients/caregivers</li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
